Table 2.

Primary endpoint: ORR

Panitumumab + rilotumumab (AMG 102)Panitumumab + ganitumab (AMG 479)Panitumumab + placebo
(n = 48)(n = 46)(n = 48)
Patients with baseline measurable disease, n (%)48 (100)46 (100)48 (100)
Objective response, n (%)15 (31)10 (22)10 (21)
 Complete response0 (0)0 (0)0 (0)
 Partial response15 (31)10 (22)10 (21)
 Stable disease19 (40)18 (39)17 (35)
 Progressive disease11 (23)15 (33)16 (33)
 Unevaluable/not done3 (6)3 (6)5 (10)
Disease control ratea, % (95% CI)71 (56–83)61 (45–75)56 (41–71)
Duration of response, median months (95% CI)5.1 (3.7–5.6)3.7 (3.6–5.8)3.7 (3.6–NE)
Posterior probability of odds ratio > 1b0.930.63

Abbreviation: NE, not estimable.

  • aDisease control rate = complete response + partial response + stable disease.

  • bOdds ratio is calculated based on ORR; an odds ratio of >1 favors the combination arm over panitumumab alone.